賴諾普利市場 - 按劑量、劑量強度、患者年齡層、應用、配銷通路- 全球預測

賴諾普利的市場規模預計在 2024 年至 2032 年間將以 4.8% 的複合年成長率成長，這主要是由於心血管疾病患病率的增加。根據世界衛生組織的數據，心血管疾病是世界上最主要的死亡原因，每年奪走約 1,790 萬人的生命。由於人口老化、久坐的生活方式和不良的飲食習慣，這些疾病變得更加普遍，對賴諾普利等有效治療方法的需求將會激增。

新興經濟體對醫療基礎設施和醫療服務的日益關注也將影響市場成長。政府和醫療保健組織正在大力投資改善醫療保健服務，並使基本藥物更容易獲得和負擔得起。賴諾普利學名藥的可用性更高，是品牌藥物的成本效益替代品，將進一步擴大產品在低收入人群中的覆蓋範圍。

該行業分為劑量、劑量強度、患者年齡層、應用、配銷通路和地區。

根據劑量，液體細分市場的賴諾普利市場將在 2024 年至 2032 年間獲得顯著的吸引力，因為它在吞嚥藥片有困難的患者（如老年人和幼兒）中越來越受歡迎。液體製劑提供了方便且易於調節的劑型，同時提高了患者的依從性並確保準確的劑量。液體賴諾普利提供的易用性和靈活性將促進該細分市場的成長。

由於全球高血壓盛行率不斷上升，預計從 2024 年到 2032 年，高血壓應用領域的賴諾普利市場將顯著成長。賴諾普利通常用於透過舒張血管和降低血壓來控制高血壓。人們對與未控制的高血壓相關的健康風險的認知不斷提高，加上篩檢和診斷方法的改進，正在刺激該細分市場的擴張。

由於經濟的快速發展和醫療基礎設施的改善，使人們更容易獲得醫療和藥品，預計亞太地區賴諾普利產業將在 2024 年至 2032 年期間顯著成長。政府加強防治非傳染性疾病，加上醫療保險覆蓋率的擴大，促進了處方藥的廣泛採用，進一步推動了區域產品需求。

目錄

第 1 章：方法與範圍

第 2 章：執行摘要

第 3 章：產業洞察

• 產業生態系統分析
• 產業影響力
  • 成長動力
    • 高血壓和心血管疾病盛行率上升
    • 人口老化加劇
    • 提高認知和篩檢計劃
    • 藥物輸送的創新
  • 產業陷阱與挑戰
    • 不良反應和安全問題
    • 替代治療方案
• 成長潛力分析
• 技術景觀
• 監管環境
• 波特的分析
• PESTEL分析

第 4 章：競爭格局

• 介紹
• 公司市佔率分析
• 競爭定位矩陣
• 戰略展望矩陣

第 5 章：市場估計與預測：按劑量，2021 - 2032

• 主要趨勢
• 藥片
• 液體

第 6 章：市場估計與預測：按劑量強度，2021 - 2032

• 主要趨勢
• 10毫克
• 20毫克
• 25毫克

第 7 章：市場估計與預測：按病患年齡層別分類，2021 - 2032 年

• 主要趨勢
• 孩子們
• 成年人

第 8 章：市場估計與預測：按應用分類，2021 - 2032

• 主要趨勢
• 高血壓
• 心臟衰竭
• 心臟病發作
• 糖尿病腎病變
• 其他應用

第 9 章：市場估計與預測：按配銷通路分類，2021 - 2032 年

• 主要趨勢
• 醫院藥房
• 零售藥房
• 網路藥房

第 10 章：市場估計與預測：按地區，2021 - 2032

• 主要趨勢
• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 英國
  • 法國
  • 西班牙
  • 義大利
  • 荷蘭
  • 歐洲其他地區
• 亞太地區
  • 日本
  • 中國
  • 印度
  • 澳洲
  • 韓國
  • 亞太地區其他地區
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
  • 拉丁美洲其他地區
• 中東和非洲
  • 沙烏地阿拉伯
  • 南非
  • 阿拉伯聯合大公國
  • 中東和非洲其他地區

第 11 章：公司簡介

• AbbVie Inc.
• Amneal Pharmaceutical, Inc.
• AstraZeneca
• Apotex Inc.
• Aurobindo Pharma Ltd.
• Bausch Health Companies, Inc.
• Cipla Limited
• Hikma Pharmaceutical PLC.
• Lupin Limited
• Merck & Co., Inc.
• Pfizer Inc.
• Sun Pharmaceutical Industries Limited
• Teva Pharmaceutical Industries Limited
• Vitaris Inc.
• Zydus Lifesciences Limited

Lisinopril market size is anticipated to grow at 4.8% CAGR between 2024 and 2032 driven primarily by the increasing prevalence of cardiovascular diseases. As per WHO, cardiovascular diseases are the world's leading cause of death, claiming approximately 17.9 million lives annually. As these conditions become more common due to aging populations, sedentary lifestyles, and poor dietary habits, the demand for effective treatments like lisinopril, will soar.

The increasing focus on healthcare infrastructure and access to medical care in emerging economies will also influence market growth. Governments and healthcare organizations are investing heavily in improving healthcare services and making essential medications more accessible and affordable. The higher availability of generic versions of lisinopril, which are cost-effective alternatives to branded drugs, will further expand the product reach among the lower-income population.

The industry is segmented into dosage, dosage strength, patient age group, application, distribution channel, and region.

Based on dosage, the lisinopril market from the liquid segment will gain significant traction between 2024 and 2032 due to its increasing popularity among patients who have difficulty swallowing pills, such as the elderly and young children. Liquid formulations offer a convenient and easily adjustable dosage form while enhancing patient compliance and ensuring accurate dosing. The ease of administration and flexibility provided by liquid lisinopril will add to the segment growth.

The lisinopril market from the hypertension application segment is anticipated to witness significant growth from 2024 to 2032 owing to the growing prevalence of hypertension worldwide. Lisinopril is commonly prescribed to manage hypertension by relaxing blood vessels and reducing blood pressure. The increasing awareness of the health risks associated with unmanaged hypertension, along with improved screening and diagnostic practices, are stimulating the segment expansion.

Asia Pacific lisinopril industry is anticipated to grow at a notable pace over 2024-2032 attributed to the rapid economic development and improving healthcare infrastructure leading to easy access to medical treatments and pharmaceuticals. Increasing government initiatives to combat non-communicable diseases, coupled with expanding health insurance coverage are facilitating greater adoption of prescription medications, further boosting the regional product demand.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising prevalence of hypertension and cardiovascular diseases
    • 3.2.1.2 Increasing aging population
    • 3.2.1.3 Growing awareness and screening programs
    • 3.2.1.4 Innovations in drug delivery
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Adverse effects and safety concerns
    • 3.2.2.2 Alternative treatment options
• 3.3 Growth potential analysis
• 3.4 Technological landscape
• 3.5 Regulatory landscape
• 3.6 Porter's analysis
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Competitive positioning matrix
• 4.4 Strategy outlook matrix

Chapter 5 Market Estimates and Forecast, By Dosage, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Tablet
• 5.3 Liquid

Chapter 6 Market Estimates and Forecast, By Dosage Strength, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 10 Mg
• 6.3 20 Mg
• 6.4 25 Mg

Chapter 7 Market Estimates and Forecast, By Patient Age Group, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Children
• 7.3 Adults

Chapter 8 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 Hypertension
• 8.3 Heart failure
• 8.4 Heart attack
• 8.5 Diabetic kidney disease
• 8.6 Other applications

Chapter 9 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

• 9.1 Key trends
• 9.2 Hospital pharmacy
• 9.3 Retail pharmacy
• 9.4 Online pharmacy

Chapter 10 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 10.1 Key trends
• 10.2 North America
  • 10.2.1 U.S.
  • 10.2.2 Canada
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 UK
  • 10.3.3 France
  • 10.3.4 Spain
  • 10.3.5 Italy
  • 10.3.6 Netherlands
  • 10.3.7 Rest of Europe
• 10.4 Asia Pacific
  • 10.4.1 Japan
  • 10.4.2 China
  • 10.4.3 India
  • 10.4.4 Australia
  • 10.4.5 South Korea
  • 10.4.6 Rest of Asia Pacific
• 10.5 Latin America
  • 10.5.1 Brazil
  • 10.5.2 Mexico
  • 10.5.3 Argentina
  • 10.5.4 Rest of Latin America
• 10.6 Middle East and Africa
  • 10.6.1 Saudi Arabia
  • 10.6.2 South Africa
  • 10.6.3 UAE
  • 10.6.4 Rest of Middle East and Africa

Chapter 11 Company Profiles

• 11.1 AbbVie Inc.
• 11.2 Amneal Pharmaceutical, Inc.
• 11.3 AstraZeneca
• 11.4 Apotex Inc.
• 11.5 Aurobindo Pharma Ltd.
• 11.6 Bausch Health Companies, Inc.
• 11.7 Cipla Limited
• 11.8 Hikma Pharmaceutical PLC.
• 11.9 Lupin Limited
• 11.10 Merck & Co., Inc.
• 11.11 Pfizer Inc.
• 11.12 Sun Pharmaceutical Industries Limited
• 11.13 Teva Pharmaceutical Industries Limited
• 11.14 Vitaris Inc.
• 11.15 Zydus Lifesciences Limited